Crinetics Pharmaceuticals Inc Forecast, price target & analysts
Crinetics Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Crinetics Pharmaceuticals Inc Classifications & Recommendation:
Crinetics Pharmaceuticals Inc Price Target
| Target Price | $81.60 |
| Price | $44.43 |
| Potential |
83.66%
register free of charge
|
| Number of Estimates | 17 |
|
17 Analysts have issued a price target Crinetics Pharmaceuticals Inc 2026 .
The average Crinetics Pharmaceuticals Inc target price is $81.60.
This is
83.66%
register free of charge
$150.15
237.95%
register free of charge
$40.40
9.07%
register free of charge
|
|
| A rating was issued by 23 analysts: 20 Analysts recommend Crinetics Pharmaceuticals Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Crinetics Pharmaceuticals Inc stock has an average upside potential 2026 of
83.66%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 1.04 | 5.92 |
| 74.06% | 469.04% | |
| EBITDA Margin | -32,314.42% | -8,043.37% |
| 484.99% | 75.11% | |
| Net Margin | -28,693.27% | -7,710.84% |
| 436.34% | 73.13% |
16 Analysts have issued a sales forecast Crinetics Pharmaceuticals Inc 2025 . The average Crinetics Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Crinetics Pharmaceuticals Inc EBITDA forecast 2025. The average Crinetics Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
18 Crinetics Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Crinetics Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.69 | -4.85 |
| 0.00% | 31.44% | |
| P/E | negative | |
| EV/Sales | 512.84 |
18 Analysts have issued a Crinetics Pharmaceuticals Inc forecast for earnings per share. The average Crinetics Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Crinetics Pharmaceuticals Inc...
Current Crinetics Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Oppenheimer |
Locked
➜
Locked
|
Locked | Sep 30 2025 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Sep 29 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Sep 29 2025 |
| Baird |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| JMP Securities |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 26 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Oppenheimer:
Locked
➜
Locked
|
Sep 30 2025 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Sep 29 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Sep 29 2025 |
|
Locked
Baird:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
JMP Securities:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 26 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Sep 24 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
